Trifluorinated Pyrimidine-Based A2B Antagonists: Optimization and Evidence of Stereospecific Recognition

Journal of Medicinal Chemistry
2019.0

Abstract

We report the identification of two subsets of fluorinated nonxanthine A2B adenosine receptor antagonists. The novel derivatives explore the effect of fluorination at different positions of two pyrimidine-based scaffolds. The most interesting ligands combine excellent hA2B affinity (Ki < 15 nM) and remarkable subtype selectivity. The results of functional cAMP experiments confirmed the antagonistic behavior of representative ligands. The compounds were designed on the basis of previous molecular models of the stereoselective binding of the parent scaffolds to the hA2B receptor, and we herein provide refinement of such models with the fluorinated compounds, which allows the explanation of the spurious effects of the fluorination at the different positions explored. These models are importantly confirmed by a synergistic study combining chiral HPLC, circular dichroism, diastereoselective synthesis, molecular modeling, and X-ray crystallography, providing experimental evidence toward the stereospecific interaction between optimized trifluorinated stereoisomers and the hA2B receptor.

Knowledge Graph

Similar Paper

Trifluorinated Pyrimidine-Based A<sub>2B</sub> Antagonists: Optimization and Evidence of Stereospecific Recognition
Journal of Medicinal Chemistry 2019.0
Enantiospecific Recognition at the A<sub>2B</sub>Adenosine Receptor by Alkyl 2-Cyanoimino-4-substituted-6-methyl-1,2,3,4-tetrahydropyrimidine-5-carboxylates
Journal of Medicinal Chemistry 2017.0
Fluorescent-Labeled Selective Adenosine A<sub>2B</sub>Receptor Antagonist Enables Competition Binding Assay by Flow Cytometry
Journal of Medicinal Chemistry 2018.0
Discovery of Potent and Highly Selective A<sub>2B</sub>Adenosine Receptor Antagonist Chemotypes
Journal of Medicinal Chemistry 2016.0
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and Analogues as A<sub>2A</sub> Adenosine Receptor Antagonists. Design, Synthesis, and Pharmacological Characterization
Journal of Medicinal Chemistry 2005.0
Discovery of 3,4-Dihydropyrimidin-2(1H)-ones As a Novel Class of Potent and Selective A<sub>2B</sub>Adenosine Receptor Antagonists
ACS Medicinal Chemistry Letters 2013.0
1-Alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: Development and Characterization of Adenosine A<sub>2B</sub>Receptor Antagonists and a New Radioligand with Subnanomolar Affinity and Subtype Specificity
Journal of Medicinal Chemistry 2009.0
N9-Benzyl-substituted 1,3-dimethyl- and 1,3-dipropyl-pyrimido[2,1-f]purinediones: Synthesis and structure–activity relationships at adenosine A1 and A2A receptors
Bioorganic &amp; Medicinal Chemistry 2007.0
(E)-1,3-Dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists
Journal of Medicinal Chemistry 1992.0
Structure−Activity Relationships at Human and Rat A<sub>2B</sub> Adenosine Receptors of Xanthine Derivatives Substituted at the 1-, 3-, 7-, and 8-Positions
Journal of Medicinal Chemistry 2002.0